Coronado Biosciences announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration, FDA, for CNDO-109, a novel biologic that primes natural killer (NK) cells without the need for cytokines (IL-2), and is being studied for the treatment of patients with high risk acute myeloid leukemia, AML, in first complete remission.
European stocks rose for a third straight session on Monday and the euro edged up, as Greek polls showed growing …
There are no comments yet